News & Events
Crinetics Reports Positive Top-Line Results from CRN04777 Phase 1 MAD Cohorts
Crinetics ($CRNX) reports results from CRN04777 Phase 1 MAD study that support potential to treat hyperinsulinism regardless of underlying genetic mutation
READ MORECrinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
Crinetics reported financial results and provided a business update, noting that key milestones were achieved, significant additional capital raised, and world-class talent added to the company from the bench to the board.
READ MORECrinetics Pharmaceuticals Appoints Chris Robillard as Chief Business Officer
Crinetics ($CRNX) appointed Chris Robillard to the role of chief business officer. Mr. Robillard is an expert in designing and implementing strategies to capitalize on growth opportunities for biopharmaceutical companies.
READ MORECrinetics Pharmaceuticals Appoints Caren Deardorf to Board of Directors
Crinetics ($CRNX) today announced the appointment of Caren Deardorf to the company’s board of directors. Ms. Deardorf previously led commercial efforts at Biogen for neurological diseases, including rare congenital disorders.
READ MORECrinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals ($CRNX) announced that the Compensation Committee granted non-qualified stock option awards to fivenew non-executive employees
READ MORECrinetics Pharmaceuticals Expands Executive Team with Appointment of James Hassard as Chief Commercial Officer
Crinetics ($CRNX) today announced the appointment of James Hassard as chief commercial officer. Mr. Hassard is a commercial leader with more than three decades of experience leading sales and marketing operations for both global and domestic biotechnology companies.
READ MORECrinetics Pharmaceuticals and Sanwa Kagaku Kenkyusho Enter into Exclusive Licensing Agreement for the Development and Commercialization of Paltusotine in Japan
Crinetics Pharmaceuticals ($CRNX) and Sanwa Kagaku Kenkyusho Co. , Ltd. have entered into a strategic partnership to develop and commercialize paltusotine in Japan.
READ MORECrinetics Pharmaceuticals to Participate in SVB Leerink Global Healthcare Conference
Crinetics Pharmaceuticals ($CRNX) will participate in a fireside chat at the annual SVB Leerink Global Healthcare Conference on February 16 at 1:00pm ET
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
